1. Home
  2. Companies
  3. IBX
  4. Material Events

Imagion Biosystems (ASX:IBX) — Material Events

ASX:IBX · 16 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 14 articles Notable 2 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
14
Imagion Biosystems Secures $3.75m to Kickstart HER2 Breast Cancer TrialMedium
Imagion Biosystems raises $3.75m to fund Phase 1b/2 HER2 breast cancer clinical trial
25 June 2026 ·Capital Raising ·85
Imagion Biosystems Advances HER2 Breast Cancer Trial with FDA IND Submission on TrackMedium
Imagion Biosystems on track for FDA IND submission and Phase 2 HER2 breast cancer trial in early 2026
1 Dec 2025 ·Company Announcement ·85
Imagion Biosystems Advances HER2 Imaging Agent with FDA Backing and $3.5M RaiseHigh
Imagion Biosystems Advances HER2 Imaging Agent with FDA Support, $3.5M Capital Raise, and IND Filing Planned for Q4 2025
21 Oct 2025 ·Quarterly Activities and Appendix 4C ·85
Imagion Biosystems Advances with FDA IND Filing for HER2 Breast Cancer Imaging TrialMedium
Imagion Biosystems lodges IND application with FDA for Phase 2 HER2 breast cancer imaging trial
2 Feb 2026 ·Company Announcement ·85
Imagion Biosystems Advances HER2 Breast Cancer Imaging with Positive WSU ResultsMedium
Imagion Biosystems Achieves Key Milestone in HER2 Breast Cancer Imaging Agent Development, IND Submission on Track for Q4 2025
5 Nov 2025 ·Company Announcement ·85
Imagion Biosystems Clears FDA Hurdle to Launch Phase 1b/2 Breast Cancer Imaging TrialMedium
Imagion Biosystems obtains FDA clearance to start Phase 1b/2 trial for MagSense HER2 Imaging Agent
2 June 2026 ·Regulatory Clearance and Clinical Trial Announcement ·85
Imagion Biosystems Accelerates HER2 Breast Cancer Imaging with Phase 2 Manufacturing and AI CollaborationMedium
Imagion Biosystems advances HER2 Breast Cancer imaging program with Phase 2 manufacturing start, new director, and AI collaboration
8 Sept 2025 ·Company Announcement ·85
Imagion Biosystems Secures Positive FDA Feedback for Breast Cancer TrialMedium
Imagion Biosystems advances MagSense HER2 breast cancer Phase 2 trial with positive FDA feedback
15 July 2025 ·Company Announcement ·80
Imagion Biosystems Advances Toward FDA Trial with New US LeadershipMedium
Imagion Biosystems Completes Manufacturing for IND Submission, Appoints New US President
29 Jan 2026 ·Quarterly Activities Report and Appendix 4C ·80
Imagion Biosystems Advances HER2 Breast Cancer Trial with Key Manufacturing MilestoneMedium
Imagion Biosystems completes HER2 imaging agent manufacturing, advances Phase 2 trial preparations with AU$3.5M raise
7 Oct 2025 ·Company Announcement ·80
Imagion Biosystems Secures $3.5M to Advance HER2+ Breast Cancer TrialMedium
Imagion Biosystems Raises A$3.5M to Fund HER2+ Breast Cancer Phase 2 Trial
4 Aug 2025 ·Capital Raising ·80
Imagion Biosystems Secures $2.85M to Propel Cancer Imaging TrialsMedium
Imagion Biosystems completes $2.85M tranche of $3.5M placement to advance cancer imaging technology
29 Sept 2025 ·Capital Raising ·75
Imagion Biosystems Advances MagSense® HER2 Amid $1.66M Half-Year Loss and $3.5M Capital RaiseMedium
Imagion Biosystems reports $1.66M half-year loss, advances MagSense® HER2 clinical development, secures $3.5M capital raise
27 Aug 2025 ·Appendix 4D Half-year report ·75
Imagion Biosystems Advances MagSense® HER2 Breast Cancer Agent with Positive FDA FeedbackMedium
Imagion Biosystems advances MagSense® HER2 breast cancer agent with positive FDA feedback and Q3 IND filing planned
29 July 2025 ·Quarterly Activities Report and Appendix 4C ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.